Literature DB >> 2241573

Modified oligopeptides designed to interact with the HIV-1 proteinase inhibit viral replication.

B Grinde1, O Hungnes, E Tjøtta.   

Abstract

The human immunodeficiency virus 1 (HIV-1) codes for a proteinase that cuts viral proteins at specific sites. We have tested 13 modified oligopeptides related to these cleavage sites to see if they inhibit viral replication. To indicate whether a decrease in replication could be due to a general inhibition of cell metabolism, we also measured the effect of the peptides on cellular protein synthesis. Three of the peptides tested (Ac-Gln-Asn-Sta-Val-NH2, Ac-Gln-Asn-Sta-Val-Val-NH2, and Ac-Glu-Asn-Sta-Ile-NH2) inhibited HIV-1 replication at concentrations that did not inhibit protein synthesis. Ac-Gln-Asn-Sta-Val-NH2 was the most potent, causing an approximately 40% decrease in viral replication, measured as the synthesis of HIV-1 antigens and the formation of infectious particles.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2241573     DOI： 10.1007/bf01310746

Source DB:  PubMed          Journal:  Arch Virol        ISSN： 0304-8608            Impact factor:   2.574


  27 in total

Review 1.  Retroviral proteases: first glimpses at the anatomy of a processing machine.

Authors:  A M Skalka
Journal:  Cell       Date:  1989-03-24       Impact factor: 41.582

2.  Inhibition of retroviral protease activity by an aspartyl proteinase inhibitor.

Authors:  I Katoh; T Yasunaga; Y Ikawa; Y Yoshinaka
Journal:  Nature       Date:  1987 Oct 15-21       Impact factor: 49.962

Review 3.  Viral proteinases.

Authors:  H G Kräusslich; E Wimmer
Journal:  Annu Rev Biochem       Date:  1988       Impact factor: 23.643

Review 4.  On the rational design of renin inhibitors: X-ray studies of aspartic proteinases complexed with transition-state analogues.

Authors:  T L Blundell; J Cooper; S I Foundling; D M Jones; B Atrash; M Szelke
Journal:  Biochemistry       Date:  1987-09-08       Impact factor: 3.162

5.  A deletion mutation in the 5' part of the pol gene of Moloney murine leukemia virus blocks proteolytic processing of the gag and pol polyproteins.

Authors:  S Crawford; S P Goff
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

6.  The proteinase inhibitor pepstatin A inhibits formation of reverse transcriptase in H9 cells infected with human immunodeficiency virus 1.

Authors:  B Grinde; O Hungnes; E Tjøtta
Journal:  AIDS Res Hum Retroviruses       Date:  1989-06       Impact factor: 2.205

7.  Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A.

Authors:  S Seelmeier; H Schmidt; V Turk; K von der Helm
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

8.  Processing of in vitro-synthesized gag precursor proteins of human immunodeficiency virus (HIV) type 1 by HIV proteinase generated in Escherichia coli.

Authors:  H G Kräusslich; H Schneider; G Zybarth; C A Carter; E Wimmer
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

9.  Renin inhibitors. Improvements in the stability and biological activity of small peptides containing novel Leu-Val replacements.

Authors:  H D Kleinert; J R Luly; P A Marcotte; T J Perun; J J Plattner; H Stein
Journal:  FEBS Lett       Date:  1988-03-28       Impact factor: 4.124

10.  Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution.

Authors:  M Miller; J Schneider; B K Sathyanarayana; M V Toth; G R Marshall; L Clawson; L Selk; S B Kent; A Wlodawer
Journal:  Science       Date:  1989-12-01       Impact factor: 47.728
View more
  1 in total

1.  Cleavage of human and mouse cytoskeletal and sarcomeric proteins by human immunodeficiency virus type 1 protease. Actin, desmin, myosin, and tropomyosin.

Authors:  R L Shoeman; C Sachse; B Höner; E Mothes; M Kaufmann; P Traub
Journal:  Am J Pathol       Date:  1993-01       Impact factor: 4.307
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.